Asthma is a widespread chronic noncommunicable disease affecting an estimated 262 million people worldwide. Sadly, asthma is often poorly managed and misunderstood, which contributed to an estimated 455,000 preventable deaths in 2019. On World Asthma Day, the Global Initiative for Asthma (GINA) and the respiratory community are calling for “Asthma Care for All” through reforms that promote equal access to quality care and improved outcomes for asthma sufferers. Asthma attacks can be physically dangerous and emotionally impactful, leading to coughing, wheezing, and shortness of breath. Exacerbations can be fatal, and there are an estimated 136 million such incidents worldwide each year. Up to 10% of people with severe uncontrollable asthma experience frequent exacerbations that significantly limit their lung function and quality of life. AstraZeneca is committed to transforming asthma care by improving the diagnosis and intervention of the disease, developing innovative medicines to eliminate attacks, and ensuring that asthma patients receive the right care, at the right time, and in the right place. AstraZeneca is also working to address the over-reliance on short-acting beta2-agonist (SABA) inhalers, which have been associated with poor asthma control and an increased risk of severe exacerbation and death. Additionally, AstraZeneca aims to reduce reliance on oral corticosteroids (OCS) in severe asthma treatment, acknowledging the associated potential for long-term health risks. The interconnection between climate and health is undeniable, making it imperative that policymakers and health system leaders prioritize asthma care reform. With billions of dollars spent on asthma care globally each year, optimizing disease management can lead to improved patient outcomes and reduce the environmental impact of asthma treatment. As a founding member of the International Respiratory Coalition, AstraZeneca supports improved access to asthma care and the reduction of lung condition burdens.
